These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28863752)

  • 21. Insights for Implementation Science From 2 Multiphased Studies With End-Users of Potential Multipurpose Prevention Technology and HIV Prevention Products.
    Minnis AM; Montgomery ET; Napierala S; Browne EN; van der Straten A
    J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 3():S222-S229. PubMed ID: 31764258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa.
    Terris-Prestholt F; Hanson K; MacPhail C; Vickerman P; Rees H; Watts C
    PLoS One; 2013; 8(12):e83193. PubMed ID: 24386160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporating end-users' voices into the development of an implant for HIV prevention: a discrete choice experiment in South Africa and Zimbabwe.
    Browne EN; Manenzhe K; Makoni W; Nkomo S; Mahaka I; Ahmed K; Shapley-Quinn MK; Marton T; Luecke E; Johnson L; van der Straten A; Minnis AM
    BMC Womens Health; 2023 Feb; 23(1):58. PubMed ID: 36765358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment.
    Browne EN; Montgomery ET; Mansfield C; Boeri M; Mange B; Beksinska M; Schwartz JL; Clark MR; Doncel GF; Smit J; Chirenje ZM; van der Straten A
    AIDS Behav; 2020 May; 24(5):1443-1451. PubMed ID: 31696371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa.
    Dietrich JJ; Atujuna M; Tshabalala G; Hornschuh S; Mulaudzi M; Koh M; Ahmed N; Muhumuza R; Ssemata AS; Otwombe K; Bekker LG; Seeley J; Martinson NA; Terris-Prestholt F; Fox J
    BMC Health Serv Res; 2021 Jan; 21(1):17. PubMed ID: 33407395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
    Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
    J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth.
    Montgomery ET; Browne EN; Atujuna M; Boeri M; Mansfield C; Sindelo S; Hartmann M; Ndwayana S; Bekker LG; Minnis AM
    J Acquir Immune Defic Syndr; 2021 Jul; 87(3):928-936. PubMed ID: 33633031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women's preferences for HIV prevention service delivery in pharmacies during pregnancy in Western Kenya: a discrete choice experiment.
    Mugambi ML; Odhiambo BO; Dollah A; Marwa MM; Nyakina J; Kinuthia J; Baeten JM; Weiner BJ; John-Stewart G; Barnabas RV; Hauber B
    J Int AIDS Soc; 2024 Jul; 27 Suppl 1(Suppl 1):e26301. PubMed ID: 38965978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045).
    Bhushan NL; Musara P; Hartmann M; Stoner MCD; Shah SR; Nabukeera J; Rukundo I; Mutero P; Lewis MA; Piper J; Shapley-Quinn MK; Etima J; Minnis AM
    J Int AIDS Soc; 2022 Oct; 25(10):e26024. PubMed ID: 36254362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.
    Young Holt B; Dellplain L; Creinin MD; Peine KJ; Romano J; Hemmerling A
    Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):326-334. PubMed ID: 30247084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
    Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
    BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region.
    Pines HA; Strathdee SA; Hendrix CW; Bristow CC; Harvey-Vera A; Magis-Rodríguez C; Martinez G; Semple SJ; Patterson TL
    Int J STD AIDS; 2019 Jan; 30(1):45-55. PubMed ID: 30170533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding women and men's acceptability of current and new HIV prevention technologies in KwaZulu-Natal, South Africa.
    Govender E; Abdool Karim Q
    AIDS Care; 2018 Oct; 30(10):1311-1314. PubMed ID: 29914270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women's attitudes to condoms and female-controlled means of protection against HIV and STDs in south-western Uganda.
    Hart GJ; Pool R; Green G; Harrison S; Nyanzi S; Whitworth JA
    AIDS Care; 1999 Dec; 11(6):687-98. PubMed ID: 10716009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of HIV prevention products on incentives to supply condomless commercial sex among female sex workers in South Africa.
    Quaife M; Vickerman P; Manian S; Eakle R; Cabrera-Escobar MA; Delany-Moretlwe S; Terris-Prestholt F
    Health Econ; 2018 Oct; 27(10):1550-1566. PubMed ID: 29926508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology.
    Ismail A; Magni S; Katahoire A; Ayebare F; Siu G; Semitala F; Kyambadde P; Friedland B; Jarrahian C; Kilbourne-Brook M
    PLoS One; 2023; 18(8):e0290568. PubMed ID: 37651432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important.
    Laher F; Salami T; Hornschuh S; Makhale LM; Khunwane M; Andrasik MP; Gray GE; Van Tieu H; Dietrich JJ
    BMC Public Health; 2020 Nov; 20(1):1669. PubMed ID: 33160341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.